Jeffrey S. Mathiesen, Chief Financial Officer at Gemphire Therapeutics Inc. (GEMP), bought 4,000 shares at $10.00 ($40K) on 2016-08-10, disclosed to the SEC on 2016-08-12.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.